Buy Stocks Easy | About Us
January 27, 2021
Buy Stocks Easy | Online Stocks

TNXP


Buy Tonix Pharmaceuticals Holding Corp. Stock (symbol: TNXP) Easy Online

Company Name: Tonix Pharmaceuticals Holding Corp.

Symbol: TNXP

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2012

TNXP Current Share Price

Today's TNXP ( Tonix Pharmaceuticals Holding Corp. ) opening price: $

Yesterday's TNXP ( Tonix Pharmaceuticals Holding Corp. ) closing price: $

Tonix Pharmaceuticals Holding Corp. Stock ( symbol: TNXP ) Price Chart since IPO (2012):

12 Months Tonix Pharmaceuticals Holding Corp. Stock ( symbol: TNXP ) Price Chart

Popular Questions about Tonix Pharmaceuticals Holding Corp. Public Stock ( TNXP )

A: Tonix Pharmaceuticals Holding Corp. stock symbol (also called stock or share ticker) is TNXP

A: Tonix Pharmaceuticals Holding Corp. IPO (Initial Public Offering) took place on 2012

A: Tonix Pharmaceuticals Holding Corp.'s stock (TNXP symbol) price at ther IPO (initial Public Offering) was $

Q: Is TNXP stock worth buying at the moment?

A: The TNXP stock performance since 2019 are rather disappointing. If you had bought 1 share of Tonix Pharmaceuticals Holding Corp. stock (symbol: TNXP) at the beginning of 2019, at the opening share price of $1.9400, you would be left with exactly $ - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Tonix Pharmaceuticals Holding Corp. Stock Easy Online

Tonix Pharmaceuticals Holding Corp. Stock Ticker Price Chart since IPO:





Tonix Pharmaceuticals Holding Corp. Stock Price Yesterday



 


Tonix Pharmaceuticals Holding Corp. Stock Price – Last Week




 


Tonix Pharmaceuticals Holding Corp. Stock Price – Last Month




 


Tonix Pharmaceuticals Holding Corp. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/16/1961200/0/en/Tonix-Pharmaceuticals-Announces-Plan-to-Develop-TNX-601-CR-Tablets-for-Once-Daily-Treatment-of-Major-Depressive-Disorder-in-Addition-to-PTSD-After-Successful-Completion-of-Phase-1-.html
                            

                                
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

                                
                                
TNX-601 CR Active Ingredient, Tianeptine, is Approved and Marketed ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/11/1959525/0/en/Tonix-Pharmaceuticals-Announces-New-European-Patent-for-the-Composition-and-Formulation-of-TNX-102-SL.html
                            

                                
Tonix Pharmaceuticals Announces New European Patent for the  Composition and Formulation of TNX-102 SL

                                
                                
NEW YORK, Dec.  11, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/10/1958440/0/en/Tonix-Pharmaceuticals-Enrolls-First-Patient-in-Phase-3-RELIEF-Study-of-TNX-102-SL-for-the-Management-of-Fibromyalgia.html
                            

                                
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

                                
                                
Interim Analysis Results Expected Second Half 2020


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/03/1955405/0/en/Tonix-Pharmaceuticals-Regains-Compliance-with-NASDAQ-Minimum-Bid-Price-Requirement.html
                            

                                
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

                                
                                
NEW YORK, Dec.  03, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/26/1952934/0/en/Tonix-Pharmaceuticals-Announces-Receipt-of-FDA-Official-Minutes-from-Breakthrough-Therapy-Type-B-Clinical-Guidance-Meeting-for-Tonmya-as-a-Potential-New-Treatment-for-PTSD.html
                            

                                
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

                                
                                
Minutes are Consistent with Guidance Received at FDA Meeting


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/11/14857755/tonix-plans-regulatory-filing-to-kick-off-study-of-alcohol-use-disorder-drug
                            

                                
Tonix Plans Regulatory Filing To Kick Off Study Of Alcohol Use Disorder Drug

                                
                                
Shares of nano-cap biotech Tonix Pharmaceuticals Holding Corp (NASD...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/21/1950749/0/en/Tonix-Pharmaceuticals-Announces-Initiation-of-the-Phase-3-RELIEF-Study-of-TNX-102-SL-for-the-Management-of-Fibromyalgia.html
                            

                                
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

                                
                                
First Patient Expected to be Dosed Before Year-End 2019 First Patie...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/20/1950392/0/en/Tonix-Pharmaceuticals-Completes-Pre-IND-Meeting-with-FDA-for-TNX-102-SL-as-a-Clinical-Candidate-for-Alcohol-Use-Disorder.html
                            

                                
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder

                                
                                
FDA Official Meeting Minutes Support Tonix’s Plan to file an Invest...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/20/1950001/0/en/Tonix-Pharmaceuticals-Announces-Closing-of-9-0-Million-Public-Offering.html
                            

                                
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering

                                
                                
NEW YORK, Nov.  20, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/15/1948016/0/en/Tonix-Pharmaceuticals-Prices-9-0-Million-Public-Offering.html
                            

                                
Tonix Pharmaceuticals Prices $9.0 Million Public Offering

                                
                                
NEW YORK, Nov.  15, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.